1-4 of 4
Jiuyang Zhang
Close
Sort by
Journal Articles

Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study

Zheng Yan, Shuna Yao, Shuang Zhao, Haiying Wang, Junfeng Chu, Yuanlin Xu, Jiuyang Zhang, Lina Zhang, Quande Lin, Lijie Liang, Ping Wang, Wenyong Li, Xiaolu Teng, Zhihua Yao, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3075.
https://doi.org/10.1182/blood-2023-185902
Published: 2023
Journal Articles

Phase II Clinical Trial of R-CHOP Combined with Lenalidomide in the First-Line Treatment for Patients with High Risk Diffuse Large B Cell Lymphoma

Shuang Zhao, Jiuyang Zhang, Zheng Yan, Yuanlin Xu, Zhihua Yao, Junfeng Chu, Shuna Yao, Haiying Wang, Wenping Zhou, Xufeng Luo, Peipei Zhang, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6237.
https://doi.org/10.1182/blood-2023-185955
Published: 2023
Journal Articles

Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

Shuang Zhao, Yanyan Liu, Zhihua Yao, Zheng Yan, Shuna Yao, Junfeng Chu, Haiying Wang, Jiuyang Zhang, Peipei Zhang, Wenping Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 6579–6580.
https://doi.org/10.1182/blood-2022-166829
Published: 2022
Journal Articles

Targeting PARP1 As an Effective Treatment for Diffuse Large B-Cell Lymphoma with High Level of γH2AX

Yanyan Liu, Peipei Zhang, Jiuyang Zhang, Wenping Zhou, Jialin Ma, Xinyang Zhao, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5799.
https://doi.org/10.1182/blood-2018-99-117590
Published: 2018